Join our growing community to challenge mainstream media bias and fix the news
Geron launches phase 3 IMpactMF clinical trial

Geron launches phase 3 IMpactMF clinical trial

Geron launches Phase 3 IMpactMF trial to evaluate Imetelstat compared to best available therapy in approximately 320 patients with Intermediate-2 or High-risk Myelofibrosis. Patients eligible for the trial will be required to be non-responsive, or refractory, to treatment with a JAK inhibitor. In a first for MF, the primary endpoint for the Phase 3 trial is Overall Survival.

Chris
Chris
Top in Sci & Tech